Last reviewed · How we verify
RBP-7000
RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period.
RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period. Used for Schizophrenia, Schizoaffective disorder.
At a glance
| Generic name | RBP-7000 |
|---|---|
| Also known as | Risperidone, Long-acting Risperidone, risperidone in Atrigel, Risperdal |
| Sponsor | Indivior Inc. |
| Drug class | Atypical antipsychotic, long-acting injectable |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
RBP-7000 uses Indivior's proprietary RBP (Risperidone Microsphere) technology to deliver risperidone as a long-acting injectable suspension. The microspheres release risperidone gradually over approximately one month, maintaining therapeutic dopamine D2 receptor blockade in the brain. This extended-release formulation improves medication adherence compared to daily oral antipsychotics.
Approved indications
- Schizophrenia
- Schizoaffective disorder
Common side effects
- Injection site pain or reaction
- Akathisia
- Extrapyramidal symptoms
- Weight gain
- Prolactin elevation
Key clinical trials
- Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients (PHASE3)
- Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy (PHASE2)
- Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia (PHASE3)
- PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia (PHASE1)
- Single Ascending Dose Study of RBP-7000 (PHASE1)
- First in Man Study of Safety, Tolerability and PK Profile of RBP-7000 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBP-7000 CI brief — competitive landscape report
- RBP-7000 updates RSS · CI watch RSS
- Indivior Inc. portfolio CI